Please login to the form below

Not currently logged in
Email:
Password:

Alprolix

This page shows the latest Alprolix news and features for those working in and with pharma, biotech and healthcare.

Sanofi extends growth spurt thanks to Genzyme, Dupixent

Sanofi extends growth spurt thanks to Genzyme, Dupixent

While growth for haemophilia treatments Eloctate and Alprolix – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – remained fairly sluggish, the quarter was marked first sales contribution ... Eloctate and Alprolix grew 4%

Latest news

  • Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

    Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... longer acting therapies such as

  • Novo Nordisk wins European approval for Refixia Novo Nordisk wins European approval for Refixia

    than standard factor IX products, meaning fewer injections are needed,. Consequently Novo is hoping the new product will help defend its franchise from rival long-acting haemophilia B drug Alprolix (eftrenonacog

  • Novo Nordisk's long-acting haemophilia B drug cleared by FDA Novo Nordisk's long-acting haemophilia B drug cleared by FDA

    Novo Nordisk has claimed US approval for Rebinyn, its long-acting Factor IX for haemophilia B, setting up a marketing battle with Bioverativ's Alprolix and CSL Behring's Idelvion. ... company does not divulge sales results, it is expected to make a

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    defend its franchise from rival long-acting haemophilia B drug Alprolix (eftrenonacog alfa) from Biogen and Swedish Orphan Biovitrum which was approved in the EU last year.

  • Biogen's CEO Scangos to step down Biogen's CEO Scangos to step down

    Long-acting Avonex follow-up Plegridy continued to gain ground - with sales up 65% to $123m - and there were also strong gains for Biogen's haemophilia drugs Eloctate and Alprolix, which

More from news
Approximately 3 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders.  During 2016 Eloctate and Alprolix

  • A rare opportunity A rare opportunity

    Last month Alprolix was approved by the European Commission, becoming the first licenced long-acting treatment for haemophilia B in the region.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics